FDA 批准 Tecentriq 联合化疗 用于 III 期 dMMR 结肠癌术后辅助治疗
美国食品药品监督管理局（FDA）10 月 9 日批准罗氏的 Tecentriq（阿替利珠单抗）联合氟嘧啶与奥沙利铂化疗，用于 III 期错配修复缺陷（dMMR）结肠癌患者术后的辅助治疗。这是该药在美国的第 12 个适应症。关键研究显示，联合方案把疾病复发或死亡风险降低约一半。GSM 提醒，是否适用须由肿瘤科医生评估，本文只作资讯，不构成医疗建议。（资料来源：FDA 与罗氏公布）
FDA Approves Tecentriq Plus Chemotherapy for Stage III dMMR Colon Cancer
The FDA on October 9 approved Roche's Tecentriq (atezolizumab) with fluoropyrimidine and oxaliplatin chemotherapy as adjuvant treatment for stage III mismatch repair-deficient (dMMR) colon cancer, the drug's 12th U.S. indication. The pivotal trial showed the combination cut the risk of recurrence or death by about half. Eligibility must be assessed by an oncologist; this item is information only, not medical advice. (Source: FDA and Roche announcements)
图片来源：图片来源：Openverse · Phil and Pam（CC BY）